Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects

NCT00709618 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
44
Enrollment
INDUSTRY
Sponsor class

Stopped Evolving standard of care practices in this disease setting was limiting enrolment and leading to a delay in delivering this study information to the public.

Conditions

Interventions

Sponsor

GlaxoSmithKline